The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Pharmacokinetics, Excretion, and Mass Balance of Liposomal Amphotericin B (AmBisome) and Amphotericin B Deoxycholate in Humans
Open accessAbstract
The pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) (liposomal AMB) and the conventional formulation, AMB deoxycholate (AMB-DOC), were compared in a phase IV, open-label, parallel study in healthy volunteers. After a single 2-h infusion of 2 mg of liposomal AMB/kg of body weight or 0.6 mg of AMB-DOC/kg, plasma, urine, and feces were collected for 168 h. The concentrations of AMB were determined by liquid chromatography tandem mass spectrometry (plasma, urine, feces) or high-performance liquid chromatography (HPLC) (plasma). Infusion-related side effects similar to those reported in patients, including nausea and back pain, were observed in both groups. Both formulations had triphasic plasma profiles with long terminal half-lives (liposomal AMB, 152 ± 116 h; AMB-DOC, 127 ± 30 h), but plasma concentrations were higher ( P < 0.01) after administration of liposomal AMB (maximum concentration of drug in serum [ C max ], 22.9 ± 10 μg/ml) than those of AMB-DOC ( C max , 1.4 ± 0.2 μg/ml). Liposomal AMB had a central compartment volume close to that of plasma (50 ± 19 ml/kg) and a volume of distribution at steady state ( V ss ) (774 ± 550 ml/kg) smaller than the V ss of AMB-DOC (1,807 ± 239 ml/kg) ( P < 0.01). Total clearances were similar (approximately 10 ml hr −1 kg −1 ), but renal and fecal clearances of liposomal AMB were 10-fold lower than those of AMB-DOC ( P < 0.01). Two-thirds of the AMB-DOC was excreted unchanged in the urine (20.6%) and feces (42.5%) with >90% accounted for in mass balance calculations at 1 week, suggesting that metabolism plays at most a minor role in AMB elimination. In contrast, <10% of the liposomal AMB was excreted unchanged. No metabolites were observed by HPLC or mass spectrometry. In comparison to AMB-DOC, liposomal AMB produced higher plasma exposures and lower volumes of distribution and markedly decreased the excretion of unchanged drug in urine and feces. Thus, liposomal AMB significantly alters the excretion and mass balance of AMB. The ability of liposomes to sequester drugs in circulating liposomes and within deep tissue compartments may account for these differences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Clinical pharmacokinetics; concepts and applications
(1989) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(89)90348-0 · Cited by 2,223
Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and Neutropenia
Walsh, T. J., Finberg, R. W., Arndt, C., Hiemenz, J., Schwartz, C., Bodensteiner, D., Pappas, P., Seibel, N., Greenberg, R. N., Dummer, S., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903113401004 · Cited by 1,205
Self-citationMechanisms of bile formation, hepatic uptake, and biliary excretion.
Klaassen, C. D., & Watkins, J. B. (1984) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06642-6 · Cited by 390
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Assessment of Pharmacokinetic Constants from Postinfusion Blood Curves Obtained after I.V. Infusion
Loo, J. C. K., & Riegelman, S. (1970) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600590107 · Cited by 301
Amphotericin B Pharmacokinetics in Humans
Atkinson, A. J., & Bennett, J. E. (1978) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.13.2.271 · Cited by 267
AmBisome (Liposomal Amphotericin B): A Comparative Review
Boswell, G. W., Buell, D., & Bekersky, I. (1998) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1998.tb04464.x · Cited by 227
Self-citationWalsh, T. J., Yeldandi, V., McEvoy, M., Gonzalez, C., Chanock, S., Freifeld, A., Seibel, N. I., Whitcomb, P. O., Jarosinski, P., Boswell, G., et al. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.9.2391 · Cited by 189
Self-citationLong Circulating Liposomes: Old Drugs, New Therapeutics
Woodle, M. C., & Storm, G. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0 · Cited by 137
Lee, J. W., Amantea, M., Francis, P. A., Navarro, E. E., Bacher, J. D., Pizzo, P. A., & Walsh, T. J. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.4.713 · Cited by 134
Self-citationFlucytosine and Amphotericin B: Hemodialysis Effects on the Plasma Concentration and Clearance
Block, E. R., BENNETT, J. E., LIVOTI, L. G., KLEIN, W. J., MacGREGOR, R. R., & HENDERSON, L. (1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-5-613 · Cited by 129
Fielding, R. M., Singer, A. W., Wang, L. H., Babbar, S., & Guo, L. S. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.2.299 · Cited by 110
Self-citationPharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients
Heinemann, V., Bosse, D., Jehn, U., Kähny, B., Wachholz, K., Debus, A., Scholz, P., Kolb, H. J., & Wilmanns, W. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.6.1275 · Cited by 107
Collette, N., van der Auwera, P., Lopez, A. P., Heymans, C., & Meunier, F. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.3.362 · Cited by 102
Lopez‐Berestein, G., Rosenblum, M. G., & Mehta, R. T. (1984) · Cancer Drug Delivery · doi:10.1089/cdd.1984.1.199 · Cited by 95
Kan, V. L., Bennett, J. E., Amantea, M., Smolskis, M. C., McManus, E., Grasela, D. M., & Sherman, J. W. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/164.2.418 · Cited by 93
Wasan, K. M., Morton, R. E., Rosenblum, M. G., & Lopez‐Berestein, G. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830716 · Cited by 82
Fielding, R. M., Lewis, R. O., & Moon-McDermott, L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011925132473 · Cited by 72
Self-citationBoswell, G. W., Bekersky, I., Buell, D. N., Hiles, R., & Walsh, T. J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.263 · Cited by 72
Self-citationSafety and Toxicokinetics of Intravenous Liposomal Amphotericin B (AmBisome ®) in Beagle Dogs
Bekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018997730462 · Cited by 63
Self-citationBekersky, I., Boswell, G. W., Hiles, R., Fielding, R. M., Buell, D. N., & Walsh, T. J. (2000) · Pharmaceutical Research · doi:10.1023/a:1007605024942 · Cited by 63
Self-citationAyestarán, A., López, R. M., Montoro, J. B., Estíbalez, A., Pou, L., Juliá, A., López, A., & Pascual, B. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.3.609 · Cited by 55
Lipid-based amphotericin B formulations: from animals to man
Bekersky, I., Fielding, R. M., Buell, D. N., & Lawrence, I. (1999) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(99)00160-1 · Cited by 50
Self-citationLee, J. W., Petersen, M. E., Lin, P., Dressler, D. E., & Bekersky, I. (2001) · Therapeutic Drug Monitoring · doi:10.1097/00007691-200106000-00015 · Cited by 46
Self-citationBekersky, I., Fielding, R. M., Dressler, D. E., Kline, S., Buell, D. N., & Walsh, T. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/009127000104100906 · Cited by 35
Self-citationKim, H., Loebenberg, D., Marco, A., Symchowicz, S., & Lin, C. (1984) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.26.4.446 · Cited by 29
Townsend, R. W., Zutshi, A., & Bekersky, I. (2001) · PubMed · Cited by 26
Self-citationClinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome®)
Fielding, R. M., Mukwaya, G., & Sandhaus, R. A. (1998) · Springer eBooks · doi:10.1007/978-3-662-22115-0_15 · Cited by 20
Self-citationFate of Liposomes In Vivo: A Brief Introductory Review
Papahadjopoulos, D. (1996) · Journal of Liposome Research · doi:10.3109/08982109609037199 · Cited by 20
Fielding, R. M. (2001) · Pharmaceutical Research · doi:10.1023/a:1011096821662 · Cited by 12
Self-citation
Cited by
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
“tericin B [71] has the theoretical potential to reduce delivery”
BackgroundSelf-citationCurrent hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
“liposomes into the bile does not occur [28].”
InfluentialAntifungal therapeutic drug monitoring: established and emerging indications
Andes, D., Pascual, A., & Marchetti, O. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00705-08 · Cited by 490
Tissue Penetration of Antifungal Agents
Felton, T., Troke, P. F., & Hope, W. W. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00046-13 · Cited by 426
Metadata
- Authors
- Bekersky, I., Fielding, R. M., Dressler, D. E., Lee, J. W., Buell, D. N., & Walsh, T. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2002-03
- Volume
- 46
- Issue
- 3
- Pages
- 828-833
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2136787592
- Cited by
- 319
- References
- 31
- FWCI
- 5.23
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.